drugset
drugset / Trial / NCT00672997

A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00672997 ↗

Phase 3 Completed 301 enrolled Alcon Research
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension. This global study will be conducted in the US (C-07-64, NCT00672997) and Japan (C-08-08, NCT00760539).

Timeline

Start
2008-05
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Background Timolol Other / unclassified 0.5 % Other
Background Travoprost Other / unclassified 0.004 % Other

Indications

ocular hypertension open-angle glaucoma